Clinical Trial Update: Intradermal BoNT-A Treatment in Erythematotelangiectatic Rosacea [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating intradermal botulinum toxin A for erythematotelangiectatic rosacea has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erythematotelangiectatic Rosacea

Drugs mentioned

• intradermal BoNT-A (botulinum toxin type A)

Snippet

Sponsor: Istanbul Training and Research Hospital | Conditions: Erythematotelangiectatic Rosacea | Phase 4 | Status: COMPLETED